RCU Labs, Inc., 408 Sunrise Avenue, Roseville, CA, 95661-4123, USA.
Cancer Immunotherapy Research Institute, 408 Sunrise Avenue, Roseville, CA, 95661, USA.
Sci Rep. 2021 Nov 23;11(1):22776. doi: 10.1038/s41598-021-02137-x.
Legalization of cannabis for medicinal and/or recreational use is expanding globally. Although cannabis is being regulated country by country, an accurate recent use test with indisputable results correlated with impairment has yet to be discovered. In the present study, a new approach for determining recent cannabis use within the impairment window after smoking was developed by studying 74 subjects with a mean age of 25 years and average use history of 9 years. Horizontal gaze nystagmus was evaluated along with subject self-assessments of impairment, and blood and breath samples were collected before and after smoking cannabis. Breath and blood pharmacokinetic parameters and cannabinoid profiles determined recent use within the impairment window. No subjects were positive for recent use pre-smoking, although all subjects had detectable cannabinoids in breath samples. We describe an inhaled cannabis recent use test that correlates with impairment and helps protect against wrongful prosecution and workplace discrimination.
大麻的药用和/或娱乐用途合法化正在全球范围内扩展。尽管大麻在各国受到监管，但尚未发现一种准确的、近期吸食大麻且结果无可争议的、与损伤相关的检测方法。在本研究中，我们通过研究 74 名平均年龄为 25 岁、平均使用大麻 9 年的受试者，开发了一种新的方法来确定吸食大麻后损伤窗口期内的近期使用情况。我们评估了水平性眼球震颤，同时让受试者自我评估损伤情况，并在吸食大麻前后采集血液和呼吸样本。呼吸和血液药代动力学参数以及大麻素图谱确定了损伤窗口期内的近期使用情况。虽然所有受试者的呼吸样本中都检测到了大麻素，但在吸烟前没有受试者呈近期使用阳性。我们描述了一种与损伤相关的吸入式大麻近期使用检测方法，有助于防止错误起诉和工作场所歧视。
